Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.61 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14238254 | 1.00 | CA2 (0.71) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL16369739 | 0.88 | SMN1; SMN2 (0.71) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL25872908 | 0.87 | ESRRG (0.61) | CA2APOBEC3AAPOBEC3GSMN1; SMN2MEN1 | |
| SCHEMBL18610093 | 0.87 | CA2 (0.69) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL6358626 | 0.87 | SMN1; SMN2 (0.75) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL6961817 | 0.86 | CA2 (0.68) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL11615300 | 0.86 | RAB9A (0.74) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL9416580 | 0.85 | HDAC6 (0.64) | CA2SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL27286669 | 0.84 | CA2 (0.66) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL4255834 | 0.84 | MMP13 (0.85) | CA2MMP13APOBEC3AAPOBEC3GSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | CA2 2007/4885MMP13 4575/4885APOBEC3A 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.